Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTA Enanta Pharmaceuticals	$5.55 +5.3%	$5.63	$4.09 ▼ $17.24	$118.40M	0.81	286,101 shs	106,054 shs
OCUP Ocuphire Pharma		$1.26	$1.07 ▼ $3.40	$30.33M	0.2	171,840 shs	676,700 shs
RAPT RAPT Therapeutics	$0.88 +16.6%	$1.02	$0.75 ▼ $4.83	$116.01M	-0.04	1.26 million shs	1.10 million shs
SLN Silence Therapeutics	$3.83 +3.5%	$3.37	$1.97 ▼ $24.38	$114.63M	1.2	298,114 shs	162,205 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTA Enanta Pharmaceuticals	0.00%	-11.43%	+12.37%	+7.55%	-58.34%
OCUP Ocuphire Pharma	0.00%	0.00%	0.00%	0.00%	-31.98%
RAPT RAPT Therapeutics	0.00%	-20.36%	-10.83%	-33.04%	-82.22%
SLN Silence Therapeutics	0.00%	-5.85%	+43.97%	-24.80%	-82.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTA Enanta Pharmaceuticals	4.155 of 5 stars	3.4	1.0	0.0	4.7	3.3	4.2	0.0
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RAPT RAPT Therapeutics	4.2822 of 5 stars	3.1	3.0	0.0	4.2	3.5	1.7	1.3
SLN Silence Therapeutics	2.646 of 5 stars	4.4	1.0	0.0	0.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$17.25	210.81% Upside
OCUP Ocuphire Pharma	3.33	Buy	$14.00	∞ Upside
RAPT RAPT Therapeutics	2.14	Hold	$4.00	355.17% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	783.38% Upside

Current Analyst Ratings Breakdown

Latest OCUP, RAPT, SLN, and ENTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00
3/10/2025	RAPT RAPT Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/7/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/5/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$49.00 ➝ $45.00
3/4/2025	SLN Silence Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$67.00 ➝ $25.00
3/4/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$6.00 ➝ $4.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTA Enanta Pharmaceuticals	$66.59M	1.78	N/A	N/A	$5.24 per share	1.06
OCUP Ocuphire Pharma	$16.45M	0.00	N/A	N/A	$2.20 per share	0.00
RAPT RAPT Therapeutics	$1.53M	75.82	N/A	N/A	$4.27 per share	0.21
SLN Silence Therapeutics	$43.26M	2.65	N/A	N/A	$0.71 per share	5.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.95	N/A	N/A	N/A	-157.57%	-75.53%	-27.30%	5/12/2025 (Estimated)
OCUP Ocuphire Pharma	-$9.99M	-$0.49	N/A	N/A	N/A	-85.75%	-30.19%	-27.55%	N/A
RAPT RAPT Therapeutics	-$116.80M	-$3.11	N/A	N/A	N/A	N/A	-89.10%	-76.13%	N/A
SLN Silence Therapeutics	-$53.82M	-$1.50	N/A	N/A	N/A	-342.00%	-62.81%	-33.89%	5/15/2025 (Estimated)

Latest OCUP, RAPT, SLN, and ENTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.16	-$1.06	+$0.10	-$1.06	$15.96 million	N/A
5/8/2025	Q1 2025	RAPT RAPT Therapeutics	-$0.31	-$0.08	+$0.23	-$0.08	N/A	N/A
3/6/2025	Q4 2024	RAPT RAPT Therapeutics	-$0.45	-$1.14	-$0.69	-$1.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A
RAPT RAPT Therapeutics	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTA Enanta Pharmaceuticals	N/A	5.47	5.47
OCUP Ocuphire Pharma	N/A	10.68	10.68
RAPT RAPT Therapeutics	N/A	9.90	9.90
SLN Silence Therapeutics	N/A	9.31	9.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTA Enanta Pharmaceuticals	94.99%
OCUP Ocuphire Pharma	14.97%
RAPT RAPT Therapeutics	99.09%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
ENTA Enanta Pharmaceuticals	13.89%
OCUP Ocuphire Pharma	8.70%
RAPT RAPT Therapeutics	2.36%
SLN Silence Therapeutics	2.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTA Enanta Pharmaceuticals	160	21.33 million	18.37 million	Optionable
OCUP Ocuphire Pharma	14	25.92 million	24.47 million	Optionable
RAPT RAPT Therapeutics	80	132.01 million	32.65 million	Optionable
SLN Silence Therapeutics	100	29.93 million	N/A	Not Optionable

OCUP, RAPT, SLN, and ENTA Headlines

Recent News About These Companies

Morgan Stanley Lowers Silence Therapeutics (NASDAQ:SLN) Price Target to $25.00

May 12 at 1:44 AM | americanbankingnews.com

Silence Therapeutics (NASDAQ:SLN) Price Target Lowered to $35.00 at Chardan Capital

May 11 at 8:43 AM | marketbeat.com

Silence Therapeutics (SLN) Projected to Post Quarterly Earnings on Thursday

May 10 at 1:53 AM | marketbeat.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Cantor Fitzgerald L. P. Buys 205,534 Shares of Silence Therapeutics plc (NASDAQ:SLN)

May 7, 2025 | marketbeat.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (NASDAQ:SLN) Stock Holdings Increased by Nantahala Capital Management LLC

April 30, 2025 | marketbeat.com

Boothbay Fund Management LLC Has $2.42 Million Position in Silence Therapeutics plc (NASDAQ:SLN)

April 30, 2025 | marketbeat.com

Marshall Wace LLP Purchases 320,472 Shares of Silence Therapeutics plc (NASDAQ:SLN)

April 28, 2025 | marketbeat.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics plc (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by Brokerages

April 20, 2025 | marketbeat.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

March 4, 2025 | zacks.com

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2025 | uk.finance.yahoo.com

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

February 28, 2025 | seekingalpha.com

Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner

February 28, 2025 | biospace.com

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025 | businesswire.com

Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell Recommendation

February 11, 2025 | msn.com

Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints

February 11, 2025 | seekingalpha.com

Silence Therapeutics initiated with a Sell at Goldman Sachs

February 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUP, RAPT, SLN, and ENTA Company Descriptions

Enanta Pharmaceuticals NASDAQ:ENTA

$5.55 +0.28 (+5.31%)

Closing price 04:00 PM Eastern

Extended Trading

$5.54 0.00 (-0.09%)

As of 04:05 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Ocuphire Pharma NASDAQ:OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

RAPT Therapeutics NASDAQ:RAPT

$0.88 +0.13 (+16.63%)

Closing price 04:00 PM Eastern

Extended Trading

$0.85 -0.03 (-2.94%)

As of 07:48 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Silence Therapeutics NASDAQ:SLN

$3.83 +0.13 (+3.51%)

Closing price 04:00 PM Eastern

Extended Trading

$3.90 +0.07 (+1.85%)

As of 07:42 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time